Ticker

Key Highlights Responder Analysis: 59.4% of patients achieved ≥30% reduction in abdominal pain; 68.1% achieved ≥30% reduction in bloating—using the FDA-recognized responder endpoint consistent with the Company's peer-reviewed randomized controlled trial. CMS Payment Rate: $300 national Medicare payment rate established, effective January 1, 2026.

Biomerica, Inc. (NASDAQ: BMRA - Get Free Report)'s stock price crossed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $2.67 and traded as low as $2.06. Biomerica shares last traded at $2.10, with a volume of 12,929 shares changing hands. Biomerica Stock Down 3.2% The company

IRVINE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced diagnostic solutions, announced that Vietnam's Hanoi Department of Health has officially approved the EZ Detect™ colorectal disease at-home screening test for sales and distribution throughout Vietnam. Biomerica is working with a major healthcare products distributor in Vietnam who will manage the sales…

Operating Expenses Decline 4% Year-to-Date Balance Sheet Strengthens and Working Capital Improves by 14.7% IRVINE, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagnostic and therapeutic products today reported financial results for the second quarter of fiscal 2026 ended November 30, 2025.

Biomerica, Inc. (NASDAQ: BMRA - Get Free Report) saw a significant growth in short interest during the month of December. As of December 31st, there was short interest totaling 92,289 shares, a growth of 123.2% from the December 15th total of 41,348 shares. Based on an average daily volume of 234,834 shares, the days-to-cover ratio is